Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it? One company pursuing a regenerative approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing biomaterial-based solutions for… Read More>> This content has been disseminated on behalf of Regentis Biomaterials Ltd. […]
- Researchers are developing new regenerative approaches, including stem cells, 3D-printed scaffolds and smart biomaterials designed to help the body repair damaged tissue.
- Focused on smart biomaterials, Regentis is advancing a hydrogel-based approach through GelrinC, a cell-free, off-the-shelf implant designed to support the regeneration of damaged knee cartilage.
- With encouraging clinical results, European approval and an ongoing U.S. pivotal trial, GelrinC is advancing toward a potential new approach to cartilage repair.
Regenerative medicine is increasingly focused on a simple but ambitious goal: rather than simply treating damaged tissue, can medicine help the body rebuild it?
Questions around this news
What is GelrinC?
GelrinC is described in the release as a cell-free, off-the-shelf implant based on hydrogel technology. Regentis is developing it to support regeneration of damaged knee cartilage. The release also reports European approval and an ongoing pivotal trial in the United States.
What is the status of GelrinC’s clinical development?
The release says GelrinC has European approval and is being evaluated in an ongoing U.S. pivotal trial. It also refers to encouraging clinical results but does not provide details about the results, trial design, enrollment, or expected timing.
How can a hydrogel implant support cartilage repair?
Hydrogels are materials that hold substantial amounts of water and can form soft, tissue-like structures. In medical applications, they may be designed to provide a supportive environment for cells or tissue processes. Their role depends on the specific material and design; the term alone does not establish how well a particular implant repairs cartilage.
One company pursuing a regenerative approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing biomaterial-based solutions for…
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NYSE American: RGNT) as part of a paid investor awareness and marketing engagement.
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer
The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT
Corporate Communications
IBN
Austin, Texas
www.InvestorBrandNetwork.com
512.354.7000 Office
[email protected]
Terms explained
- Hydrogel
- A water-rich material formed from a network of polymers. Depending on its composition, it can be made soft and flexible for uses such as medical implants.
- Cell-free
- Describes a product or treatment that does not contain living cells as an active component.
- Off-the-shelf
- Describes a product made and stored in advance for use when needed, rather than prepared specifically for an individual patient.
- Pivotal trial
- A clinical study intended to provide important evidence about a medical product’s safety and effectiveness, often to support a regulatory decision.
- Biomaterial
- A material designed to interact with biological systems, for example as part of a medical device, implant, or tissue-repair approach.
SEC filings
Earlier from Regentis Biomaterials Ltd.
- Regentis Biomaterials (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks
- Regentis Biomaterials (NYSE American: RGNT) Builds a Manufacturing and Intellectual Property Powerhouse for the Global Cartilage Repair Market
- Regentis Biomaterials (NYSE American: RGNT) Targets $3B Cartilage Repair Market with Cell-Free Gelrin C
- Regentis Biomaterials (NYSE American: RGNT) Receives European Approval for Next-Generation GelrinC Manufacturing Process
- Regentis Biomaterials (NYSE American: RGNT) Advances European Commercial Launch Plans for GelrinC
